ISAL 2019 | The benefits of dual-targeting triplebodies

Name: The benefits of dual-targeting triplebodies
Uploaded: 2019-03-15T12:21:03.000Z
Duration: 2 min 3 s
Description: Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, explains the benefits of dual-targeting triplebodies.

Georg Fey • 15 Mar 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia Antibodies SPM-2

Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, explains the benefits of dual-targeting triplebodies.